DiMeglio LA, Evans-Molina C, Oram RA. Type 1 diabetes. Lancet. 2018;391:2449–62. https://doi.org/10.1016/S0140-6736(18)31320-5.

Article  PubMed  PubMed Central  Google Scholar 

Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, Stein C, Basit A, Chan JCN, Mbanya JC, Pavkov ME, Ramachandaran A, Wild SH, James S, Herman WH, Zhang P, Bommer C, Kuo S, Boyko EJ, Magliano DJ. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119. https://doi.org/10.1016/j.diabres.2021.109119.

Article  PubMed  Google Scholar 

Katsarou A, Gudbjörnsdottir S, Rawshani A, Dabelea D, Bonifacio E, Anderson BJ, Jacobsen LM, Schatz DA, Lernmark Å. Type 1 diabetes mellitus. Nat Rev Dis Primers. 2017;3:17016. https://doi.org/10.1038/nrdp.2017.16.

Article  PubMed  Google Scholar 

Eisenbarth GS. Type I diabetes mellitus. A chronic autoimmune disease. N Engl J Med. 1986;314:1360–8.

Article  CAS  PubMed  Google Scholar 

Umpierrez G, Korytkowski M. Diabetic emergencies-ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia. Nat Rev Endocrinol. 2016;12:222–32. https://doi.org/10.1038/nrendo.2016.15.

Article  CAS  PubMed  Google Scholar 

Dhatariya KK, Glaser NS, Codner E, Umpierrez GE. Diabetic ketoacidosis. Nature reviews. Dis Primers. 2020;6:40. https://doi.org/10.1038/s41572-020-0165-1.

Article  Google Scholar 

Ni Q, Pham NB, Meng WS, Zhu G, Chen X. Advances in immunotherapy of type I diabetes. Adv Drug Deliv Rev. 2019;139:83–91. https://doi.org/10.1016/j.addr.2018.12.003.

Article  CAS  PubMed  Google Scholar 

Ilonen J, Lempainen J, Veijola R. The heterogeneous pathogenesis of type 1 diabetes mellitus. Nat Rev Endocrinol. 2019;15:635–50. https://doi.org/10.1038/s41574-019-0254-y.

Article  CAS  PubMed  Google Scholar 

Pang H, Xia Y, Luo S, Huang G, Li X, Xie Z, Zhou Z. Emerging roles of rare and low-frequency genetic variants in type 1 diabetes mellitus. J Med Genet. 2021;58:289–96. https://doi.org/10.1136/jmedgenet-2020-107350.

Article  CAS  PubMed  Google Scholar 

Torun A, Hupalowska A, Trzonkowski P, Kierkus J, Pyrzynska B. Intestinal microbiota in common chronic inflammatory disorders affecting children. Front Immunol. 2021;12:642166. https://doi.org/10.3389/fimmu.2021.642166.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sims EK, Carr ALJ, Oram RA, DiMeglio LA, Evans-Molina C. 100 years of insulin: celebrating the past, present and future of diabetes therapy. Nat Med. 2021;27:1154–64. https://doi.org/10.1038/s41591-021-01418-2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yu X, Zhang S, Zhang L. Newer Perspectives of mechanisms for euglycemic diabetic ketoacidosis. Int J Endocrinol. 2018;2018:7074868. https://doi.org/10.1155/2018/7074868.

Article  PubMed  PubMed Central  Google Scholar 

Long B, Lentz S, Koyfman A, Gottlieb M. Euglycemic diabetic ketoacidosis: Etiologies, evaluation, and management. Am J Emerg Med. 2021;44:157–60. https://doi.org/10.1016/j.ajem.2021.02.015.

Article  PubMed  Google Scholar 

Thiruvenkatarajan V, Meyer EJ, Nanjappa N, Van Wijk RM, Jesudason D. Perioperative diabetic ketoacidosis associated with sodium-glucose co-transporter-2 inhibitors: a systematic review. Br J Anaesth. 2019;123:27–36. https://doi.org/10.1016/j.bja.2019.03.028.

Article  CAS  PubMed  Google Scholar 

Bradley CA. Immunotherapy: PDL1 restoration reverses T1DM. Nat Rev Endocrinol. 2018;14:1. https://doi.org/10.1038/nrendo.2017.165.

Article  PubMed  Google Scholar 

Vallianou NG, Stratigou T, Geladari E, Tessier CM, Mantzoros CS, Dalamaga M. Diabetes type 1: can it be treated as an autoimmune disorder? Rev Endocr Metab Disord. 2021;22:859–76. https://doi.org/10.1007/s11154-021-09642-4.

Article  PubMed  Google Scholar 

Nagy G, Szekely TE, Somogyi A, Herold M, Herold Z. New therapeutic approaches for type 1 diabetes: disease-modifying therapies. World J Diabetes. 2022;13:835–50. https://doi.org/10.4239/wjd.v13.i10.835.

Article  PubMed  PubMed Central  Google Scholar 

Pociot F, Lernmark Å. Genetic risk factors for type 1 diabetes. Lancet. 2016;387:2331–9. https://doi.org/10.1016/S0140-6736(16)30582-7.

Article  CAS  PubMed  Google Scholar 

Cabello-Olmo M, Araña M, Radichev I, Smith P, Huarte E, Barajas M. New insights into immunotherapy strategies for treating autoimmune diabetes. Int J Mol Sci. 2019. https://doi.org/10.3390/ijms20194789.

Article  PubMed  PubMed Central  Google Scholar 

Wong FS, Wen L. A predictive CD8 T cell phenotype for T1DM progression. Nat Rev Endocrinol. 2020;16:198–9. https://doi.org/10.1038/s41574-020-0330-3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ke Q, Kroger CJ, Clark M, Tisch RM. evolving antibody therapies for the treatment of type 1 diabetes. Front Immunol. 2020;11:624568. https://doi.org/10.3389/fimmu.2020.624568.

Article  CAS  PubMed  Google Scholar 

Brown CC, Gudjonson H, Pritykin Y, Deep D, Lavallee VP, Mendoza A, Fromme R, Mazutis L, Ariyan C, Leslie C, Pe’er D, Rudensky AY. Transcriptional basis of mouse and human dendritic cell heterogeneity. Cell. 2019;179:846-863e824. https://doi.org/10.1016/j.cell.2019.09.035.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Szabo CE, Ilies RF, Aioanei CS, Catana A, Cret V, Serban RS, Pop IV. The role of adiponectin, TNF-alpha and glutathione in the pathogenesis and evolution of type 1 diabetes. Diabetes Metab Syndr Obes. 2019;12:2303–8. https://doi.org/10.2147/DMSO.S220133.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tampio J, Markowicz-Piasecka M, Huttunen KM. Hemocompatible L-Type amino acid transporter 1 (LAT1)-Utilizing prodrugs of perforin inhibitors can accumulate into the pancreas and alleviate inflammation-induced apoptosis. Chem Biol Interact. 2021;345:109560. https://doi.org/10.1016/j.cbi.2021.109560.

Article  CAS  PubMed  Google Scholar 

Li X, Liao M, Guan J, Zhou L, Shen R, Long M, Shao J. Identification of key genes and pathways in peripheral blood mononuclear cells of type 1 diabetes mellitus by integrated bioinformatics analysis. Diabetes Metab J. 2022;46:451–63. https://doi.org/10.4093/dmj.2021.0018.

Article  PubMed  PubMed Central  Google Scholar 

Pugliese A. Autoreactive T cells in type 1 diabetes. J Clin Invest. 2017;127:2881–91. https://doi.org/10.1172/JCI94549.

Article  PubMed  PubMed Central  Google Scholar 

Leete P, Willcox A, Krogvold L, Dahl-Jørgensen K, Foulis AK, Richardson SJ, Morgan NG. Differential insulitic profiles determine the extent of β-cell destruction and the age at onset of type 1 diabetes. Diabetes. 2016;65:1362–9. https://doi.org/10.2337/db15-1615.

Article  CAS  PubMed  Google Scholar 

Ghonaim MM, El-Edel RH, Kamal Eldein SM, Abo El Fotoh WMM, Salman SS. T-regulatory cell subsets in children with type 1 diabetes mellitus: relation to control of the disease. Endocr Metab Immune Disord Drug Targets. 2017;17:238–45. https://doi.org/10.2174/1871530317666170818115116.

Article  CAS  PubMed  Google Scholar 

Jeyam A, Colhoun H, McGurnaghan S, Blackbourn L, McDonald TJ, Palmer CNA, McKnight JA, Strachan MWJ, Patrick AW, Chalmers J, Lindsay RS, Petrie JR, Thekkepat S, Collier A, MacRury S, McKeigue PM. Clinical impact of residual C-peptide secretion in type 1 diabetes on glycemia and microvascular complications. Diabetes Care. 2021;44:390–8. https://doi.org/10.2337/dc20-0567.

Article  CAS  PubMed  Google Scholar 

Herold KC, Gitelman SE, Ehlers MR, Gottlieb PA, Greenbaum CJ, Hagopian W, Boyle KD, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, McNamara J, Bluestone JA. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes. 2013;62:3766–74. https://doi.org/10.2337/db13-0345.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rigby MR, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Patel CM, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Moran A, Russell WE, Pinckney A, Keyes-Elstein L, Howell M, Aggarwal S, Lim N, Phippard D, Nepom GT, McNamara J, Ehlers MR. Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Diabetes Endocrinol. 2013;1:284–94. https://doi.org/10.1016/S2213-8587(13)70111-6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Akil AA-S, Yassin E, Al-Maraghi A, Aliyev E, Al-Malki K, Fakhro KA. Diagnosis and treatment of type 1 diabetes at the dawn of the personalized medicine era. J Transl Med. 2021;19:137. https://doi.org/10.1186/s12967-021-02778-6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Morgan NG. Bringing the human pancreas into focus: new paradigms for the understanding of Type 1 diabetes. Diabet Med. 2017;34:879–86. https://doi.org/10.1111/dme.13365.

Article  CAS  PubMed  Google Scholar 

Eizirik DL, Pasquali L, Cnop M. Pancreatic β-cells in type 1 and type 2 diabetes mellitus: different pathways to failure. Nat Rev Endocrinol. 2020;16:349–62. https://doi.org/10.1038/s41574-020-0355-7.

Article